[Sorafenib: effectiveness versus safety. Prevention of hand-foot syndrome].
L
L
Delgado-Téllez
M A
MA
Campos Fernández de Sevilla
Federico
F
Tutau
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000517:prevention & control; D005533:Foot Dermatoses / Q000209:etiology* / Q000517:prevention & control; D006229:Hand Dermatoses / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib